These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9595995)

  • 1. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Kissel JT; McDermott MP; Natarajan R; Mendell JR; Pandya S; King WM; Griggs RC; Tawil R
    Neurology; 1998 May; 50(5):1402-6. PubMed ID: 9595995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.
    Kissel JT; McDermott MP; Mendell JR; King WM; Pandya S; Griggs RC; Tawil R;
    Neurology; 2001 Oct; 57(8):1434-40. PubMed ID: 11673585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strength training and albuterol in facioscapulohumeral muscular dystrophy.
    van der Kooi EL; Vogels OJ; van Asseldonk RJ; Lindeman E; Hendriks JC; Wohlgemuth M; van der Maarel SM; Padberg GW
    Neurology; 2004 Aug; 63(4):702-8. PubMed ID: 15326246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment for facioscapulohumeral muscular dystrophy.
    Rose MR; Tawil R
    Cochrane Database Syst Rev; 2004; 2004(2):CD002276. PubMed ID: 15106171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Tawil R; McDermott MP; Pandya S; King W; Kissel J; Mendell JR; Griggs RC
    Neurology; 1997 Jan; 48(1):46-9. PubMed ID: 9008492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.
    van der Kooi EL; Kalkman JS; Lindeman E; Hendriks JC; van Engelen BG; Bleijenberg G; Padberg GW
    J Neurol; 2007 Jul; 254(7):931-40. PubMed ID: 17361345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy.
    Fowler EG; Graves MC; Wetzel GT; Spencer MJ
    Neurology; 2004 Mar; 62(6):1006-8. PubMed ID: 15037714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial.
    Payan CA; Hogrel JY; Hammouda EH; Lacomblez L; Ollivier G; Doppler V; Eymard B; Attarian S; Pouget J; Desnuelle C; Laforêt P
    Arch Phys Med Rehabil; 2009 Jul; 90(7):1094-101. PubMed ID: 19577021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot trial of albuterol in spinal muscular atrophy.
    Kinali M; Mercuri E; Main M; De Biasia F; Karatza A; Higgins R; Banks LM; Manzur AY; Muntoni F
    Neurology; 2002 Aug; 59(4):609-10. PubMed ID: 12196659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy.
    Skura CL; Fowler EG; Wetzel GT; Graves M; Spencer MJ
    Neurology; 2008 Jan; 70(2):137-43. PubMed ID: 17942817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.
    Neurology; 1997 Jan; 48(1):38-46. PubMed ID: 9008491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD).
    Skalsky AJ; Abresch RT; Han JJ; Shin CS; McDonald CM
    Neuromuscul Disord; 2008 Nov; 18(11):873-80. PubMed ID: 18818077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy.
    Wang LH; Leung DG; Wagner KR; Lowry SJ; McDermott MP; Eichinger K; Higgs K; Walker M; Lewis L; Martens WB; Mul K; Sansone VA; Shieh P; Elsheikh B; LoRusso S; Butterfield RJ; Johnson N; Preston MR; Messina C; Carraro E; Tawil R; Statland J;
    Neuromuscul Disord; 2023 Sep; 33(9):63-68. PubMed ID: 37400350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD).
    Varma A; Todinca MS; Eichinger K; Heininger S; Dilek N; Martens W; Tawil R; Statland J; Kissel JT; McDermott MP; Heatwole C
    Muscle Nerve; 2024 Mar; 69(3):362-367. PubMed ID: 38189531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic trial of beta 2-adrenergic agonist clenbuterol in muscular dystrophies].
    Oya Y; Ogawa M; Kawai M
    Rinsho Shinkeigaku; 2001 Oct; 41(10):698-700. PubMed ID: 11993192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial.
    Passerieux E; Hayot M; Jaussent A; Carnac G; Gouzi F; Pillard F; Picot MC; Böcker K; Hugon G; Pincemail J; Defraigne JO; Verrips T; Mercier J; Laoudj-Chenivesse D
    Free Radic Biol Med; 2015 Apr; 81():158-69. PubMed ID: 25246239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group.
    Tawil R; McDermott MP; Mendell JR; Kissel J; Griggs RC
    Neurology; 1994 Mar; 44(3 Pt 1):442-6. PubMed ID: 8145913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.
    Personius KE; Pandya S; King WM; Tawil R; McDermott MP
    Phys Ther; 1994 Mar; 74(3):253-63. PubMed ID: 8115459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strength training and aerobic exercise training for muscle disease.
    van der Kooi EL; Lindeman E; Riphagen I
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003907. PubMed ID: 15674918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.